HRH3 and Alzheimer disease: Recently phase II trials of H3R antagonists ABT-288 (NCT-ID NCT01018875), GSK239512 (NCT-ID NCT01009255), and MK0249 (NCT-ID NCT00420420) for mild to moderate AD have been completed.